leadf
logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences: Advancing at speed

Tiziana (TILS), also listed on NASDAQ (Symbol TLSA), is driving forwards the clinical development plan for its fully-human mAb TZLS-501 for treating COVID-19 respiratory symptoms and has set out the detail of its clinical plan being executed by a group of specialist contract research organisations (CROs). With GMP-grade manufacturing already underway via boutique CRO, STC Biologics, the company has appointed three other CROs to develop and test the handheld nebuliser, to conduct an inhalation safety toxicity study in monkeys, and to initiate a human clinical trial in COVID-19 patients.

Having recently announced a US$57mln gross equity offer, subject to imminent closure, TILS looks well set to execute its clinical development strategy both for TZLS-501 and for the full clinical pipeline which includes phase II studies of its proprietary nasal and oral formulations of its lead candidate Foralumab, a fully-human anti-CD3 specific mAb with broad potential to treat inflammatory and autoimmune diseases.

TILS has taken an innovative approach to leverage the potential of TZLS-501 to treat COVID-19, to investigate its promise of helping alleviate life-threatening lung inflammation. To our knowledge TILS is a pioneer in developing anti-IL6R mAbs for administration via a nebuliser or inhaler direct to the lungs and recently filed a patent on the approach in order to target the main site of inflammation directly.

 

 

Quick facts: Tiziana Life Sciences PLC

Price: 140.55 GBX

AIM:TILS
Market: AIM
Market Cap: £269.07 m
Follow

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Tiziana Life Sciences: Delivery method & data 'looks promising' ahead of...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially...

1 week, 2 days ago

4 min read